Lucid Announces Fourth Quarter and Full Year 2022 Financial Results, Exceeds Annual Production Guidance With 3,493 Vehicles in Q4 and 7,180 in the Full Year 2022
- 3,493 vehicles produced in Q4, up 53 percent sequentially
- 7,180 vehicles produced in 2022, exceeding annual production guidance of 6,000 to 7,000 vehicles
- Q4 revenue of over
$257M and annual revenue of over$608M - Ended the quarter with approximately
$4.9B total liquidity - 2023 production guidance of 10,000 to 14,000 vehicles
Lucid reported fourth quarter revenue of
"Last year was a challenging year for everyone, yet despite the extraordinary supply chain and logistics challenges, the team persevered with an unrelenting focus on delivering what we believe is the best luxury sedan on the market," said
"
"In 2022, we scaled every part of our business while keeping a sharp focus on execution. In our first full year of production, we manufactured 7,180 vehicles and delivered 4,369 vehicles, generating revenue of just over
About
Lucid's mission is to inspire the adoption of sustainable energy by creating advanced technologies and the most captivating luxury electric vehicles centered around the human experience.
Investor Relations Contact
Media Contact
Trademarks
This communication contains trademarks, service marks, trade names and copyrights of Lucid Group, Inc. and its subsidiaries and other companies, which are the property of their respective owners.
Forward Looking Statements
This communication includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "shall," "expect," "anticipate," "believe," "seek," "target," "continue," "could," "may," "might," "possible," "potential," "predict" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding financial and operating outlook and guidance, amount of reservations and related potential sales, future capital expenditures and other operating expenses, ability to control costs, expectations and timing related to commercial product launches, including the Gravity SUV and the various Air models, production and delivery volumes, expectations regarding market opportunities and demand for Lucid's products, the range and performance of Lucid's vehicles, plans and expectations regarding Lucid's software, product recalls, estimate of the length of time Lucid's existing cash, cash equivalents and investments will be sufficient to fund planned operations, plans and expectations regarding its future capital raises and funding strategy, the timing of deliveries, future manufacturing capabilities and facilities, studio and service center openings, ability to mitigate supply chain and logistics risks, plans regarding the Phase 2 expansion of Lucid's AMP-1 factory, including timing, installed capacity and potential benefits, ability to vertically integrate production processes, future sales channels and strategies, future market launches and international expansion, including plans for the European and Middle Eastern markets and the AMP-2 manufacturing facility in
Non-GAAP Financial Measures and Key Business Metrics
Consolidated financial information has been presented in accordance with US GAAP ("GAAP") as well as on a non-GAAP basis to supplement our consolidated financial results. Lucid's non-GAAP financial measures include Adjusted EBITDA and Free Cash Flow which are discussed below.
Adjusted EBITDA is defined as net loss before (1) interest expense, (2) interest income, (3) provision for (benefit from) income taxes, (4) depreciation and amortization, (5) change in fair value of forward contracts, (6) change in fair value of convertible preferred stock warrant liability, (7) change in fair value of common stock warrant liability, (8) transaction costs expensed and (9) stock-based compensation. Adjusted EBITDA is a performance measure that Lucid believes provides useful information to Lucid's management and investors about Lucid's profitability. Free Cash Flow is defined as net cash used in operating activities less capital expenditures. Free Cash Flow is a performance measure that Lucid believes provides useful information to Lucid's management and investors about the amount of cash generated by the business after necessary capital expenditures.
These non-GAAP financial measures facilitate management's internal comparisons to Lucid's historical performance. Management believes that it is useful to supplement its GAAP financial statements with this non-GAAP information because management uses such information internally for its operating, budgeting, and financial planning purposes. Management also believes that presentation of the non-GAAP financial measures provides useful information to Lucid's investors regarding measures of our financial condition and results of operations that Lucid uses to run the business and therefore allows investors to better understand Lucid's performance. However, these non-GAAP financial and key performance measures have limitations as analytical tools and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP.
Non-GAAP information is not prepared under a comprehensive set of accounting rules and therefore, should only be read in conjunction with financial information reported under GAAP when understanding Lucid's operating performance. In addition, other companies, including companies in Lucid's industry, may calculate non-GAAP financial measures and key performance measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Lucid's non-GAAP financial measures and key performance measures as tools for comparison. A reconciliation between GAAP and non-GAAP financial information is presented below.
|
||||
|
|
|||
ASSETS |
||||
Current assets: |
||||
Cash and cash equivalents |
$ 1,735,765 |
$ 6,262,905 |
||
Short-term investments |
2,177,231 |
— |
||
Accounts receivable, net |
19,542 |
3,148 |
||
Inventory |
834,401 |
127,250 |
||
Prepaid expenses |
63,548 |
70,346 |
||
Other current assets |
81,541 |
43,328 |
||
Total current assets |
4,912,028 |
6,506,977 |
||
Property, plant and equipment, net |
2,166,776 |
1,182,153 |
||
Right-of-use assets |
215,160 |
161,974 |
||
Long-term investments |
529,974 |
— |
||
Other noncurrent assets |
55,300 |
30,609 |
||
TOTAL ASSETS |
$ 7,879,238 |
$ 7,881,713 |
||
LIABILITIES AND STOCKHOLDERS' EQUITY |
||||
Current liabilities: |
||||
Accounts payable |
$ 229,084 |
$ 41,342 |
||
Accrued compensation |
63,322 |
32,364 |
||
Finance lease liabilities, current portion |
10,586 |
4,183 |
||
Other current liabilities |
634,567 |
318,212 |
||
Total current liabilities |
937,559 |
396,101 |
||
Finance lease liabilities, net of current portion |
81,336 |
6,083 |
||
Common stock warrant liability |
140,590 |
1,394,808 |
||
Long-term debt |
1,991,840 |
1,986,791 |
||
Other long-term liabilities |
378,212 |
188,575 |
||
Total liabilities |
3,529,537 |
3,972,358 |
||
STOCKHOLDERS' EQUITY |
||||
Preferred stock, par value 2021; no shares issued and outstanding as of |
— |
— |
||
Common stock, par value |
183 |
165 |
||
Additional paid-in capital |
11,752,138 |
9,995,778 |
||
|
(20,716) |
(20,716) |
||
Accumulated other comprehensive loss |
(11,572) |
— |
||
Accumulated deficit |
(7,370,332) |
(6,065,872) |
||
Total stockholders' equity |
4,349,701 |
3,909,355 |
||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ 7,879,238 |
$ 7,881,713 |
|
|||||||
Three Months Ended |
Twelve Months Ended |
||||||
2022 |
2021 |
2022 |
2021 |
||||
Revenue |
$ 257,713 |
$ 26,392 |
$ 608,181 |
$ 27,111 |
|||
Costs and expenses |
|||||||
Cost of revenue |
615,291 |
151,473 |
1,646,086 |
154,897 |
|||
Research and development |
221,294 |
163,606 |
821,512 |
750,185 |
|||
Selling, general and administrative |
170,867 |
196,997 |
734,574 |
652,475 |
|||
Total cost and expenses |
1,007,452 |
512,076 |
3,202,172 |
1,557,557 |
|||
Loss from operations |
(749,739) |
(485,684) |
(2,593,991) |
(1,530,446) |
|||
Other income (expense), net |
|||||||
Change in fair value of forward contracts |
— |
— |
— |
(454,546) |
|||
Change in fair value of convertible preferred stock warrant liability |
— |
— |
— |
(6,976) |
|||
Change in fair value of common stock warrant liability |
255,899 |
(557,973) |
1,254,218 |
(582,760) |
|||
Transaction costs expensed |
— |
— |
— |
(2,717) |
|||
Interest income |
29,472 |
— |
56,756 |
— |
|||
Interest expense |
(8,075) |
(1,263) |
(30,596) |
(1,374) |
|||
Other income (expense), net |
(366) |
(742) |
9,532 |
(893) |
|||
Total other income (expense), net |
276,930 |
(559,978) |
1,289,910 |
(1,049,266) |
|||
Loss before provision for (benefit from) income taxes |
(472,809) |
(1,045,662) |
(1,304,081) |
(2,579,712) |
|||
Provision for (benefit from) income taxes |
(161) |
18 |
379 |
49 |
|||
Net loss |
(472,648) |
(1,045,680) |
(1,304,460) |
(2,579,761) |
|||
Deemed dividend related to the issuance of Series E convertible preferred |
— |
— |
— |
(2,167,332) |
|||
Net loss attributable to common stockholders, basic |
(472,648) |
(1,045,680) |
(1,304,460) |
(4,747,093) |
|||
Change in fair value of dilutive warrants |
— |
— |
(1,254,218) |
— |
|||
Net loss attributable to common stockholders, diluted |
$ (472,648) |
$ (1,045,680) |
$ (2,558,678) |
$ (4,747,093) |
|||
Weighted average shares outstanding used in computing net loss per share |
1,712,951,982 |
1,636,215,509 |
1,678,346,079 |
740,393,759 |
|||
Weighted average shares outstanding used in computing net loss per share |
1,712,951,982 |
1,636,215,509 |
1,693,258,608 |
740,393,759 |
|||
Net loss per share attributable to common stockholders, basic |
$ (0.28) |
$ (0.64) |
$ (0.78) |
$ (6.41) |
|||
Net loss per share attributable to common stockholders, diluted |
$ (0.28) |
$ (0.64) |
$ (1.51) |
$ (6.41) |
|||
Other comprehensive loss |
|||||||
Net unrealized gains (losses) on investments, net of tax |
$ 1,694 |
$ — |
$ (11,572) |
$ — |
|||
Comprehensive loss |
(470,954) |
(1,045,680) |
(1,316,032) |
(2,579,761) |
|||
Deemed dividend related to the issuance of Series E convertible preferred |
— |
— |
— |
(2,167,332) |
|||
Comprehensive loss attributable to common stockholders |
$ (470,954) |
$ (1,045,680) |
$ (1,316,032) |
$ (4,747,093) |
|
|||||||
Three Months Ended |
Twelve Months Ended |
||||||
2022 |
2021 |
2022 |
2021 |
||||
Cash flows from operating activities |
|||||||
Net loss |
$ (472,648) |
$ (1,045,680) |
$ (1,304,460) |
$ (2,579,761) |
|||
Adjustments to reconcile net loss to net cash used in operating activities: |
|||||||
Depreciation and amortization |
55,240 |
36,286 |
186,583 |
62,907 |
|||
Amortization of insurance premium |
10,432 |
11,290 |
35,620 |
18,474 |
|||
Non-cash operating lease cost |
5,457 |
3,934 |
19,711 |
12,563 |
|||
Stock-based compensation |
71,255 |
150,557 |
423,500 |
516,757 |
|||
Inventory and firm purchase commitments write-downs |
204,926 |
48,884 |
569,479 |
48,884 |
|||
Change in fair value of contingent forward contract liability |
— |
— |
— |
454,546 |
|||
Change in fair value of preferred stock warrant liability |
— |
— |
— |
6,976 |
|||
Change in fair value of common stock warrant liability |
(255,899) |
557,973 |
(1,254,218) |
582,760 |
|||
Other non-cash items |
(5,322) |
233 |
(10,342) |
289 |
|||
Changes in operating assets and liabilities: |
|||||||
Accounts receivable |
(16,987) |
(2,887) |
(16,498) |
(2,888) |
|||
Inventory |
(350,295) |
(114,979) |
(1,256,349) |
(175,091) |
|||
Prepaid expenses |
(16,721) |
(1,283) |
(28,822) |
(66,980) |
|||
Other current assets |
(10,329) |
(23,003) |
(43,591) |
(14,704) |
|||
Other noncurrent assets |
(4,148) |
11,750 |
(43,230) |
5,889 |
|||
Accounts payable |
128,253 |
18,529 |
180,469 |
4,354 |
|||
Accrued compensation |
14,314 |
3,415 |
30,958 |
16,167 |
|||
Operating lease liability |
(4,721) |
(5,503) |
(15,482) |
(10,019) |
|||
Other current liabilities |
(12,159) |
47,622 |
269,386 |
65,456 |
|||
Other long-term liabilities |
10,837 |
(9,870) |
31,028 |
(4,712) |
|||
Net cash used in operating activities |
(648,515) |
(312,732) |
(2,226,258) |
(1,058,133) |
|||
Cash flows from investing activities: |
|||||||
Purchases of property, plant and equipment |
(289,888) |
(121,907) |
(1,074,852) |
(421,220) |
|||
Proceeds from sale of property, plant and equipment |
— |
3 |
— |
22 |
|||
Proceeds from government grant |
— |
— |
97,267 |
— |
|||
Purchases of investments |
(1,127,452) |
— |
(3,854,129) |
— |
|||
Proceeds from maturities of investments |
1,024,361 |
— |
1,149,714 |
— |
|||
Proceeds from sale of short term investments |
— |
505 |
— |
505 |
|||
Proceeds from insurance claims |
323 |
— |
323 |
— |
|||
Net cash used in investing activities |
(392,656) |
(121,399) |
(3,681,677) |
(420,693) |
|||
Cash flows from financing activities: |
|||||||
Proceed from issuance of convertible notes, net of issuance costs |
— |
2,002,437 |
— |
2,002,437 |
|||
Payment of transaction costs for the issuance of convertible notes |
— |
(15,883) |
— |
(15,883) |
|||
Proceeds from issuance of common stock under At-the-Market Offering, net of issuance costs |
594,317 |
— |
594,317 |
— |
|||
Proceeds from issuance of common stock under Subscription Agreement |
915,000 |
— |
915,000 |
— |
|||
Proceeds from short-term insurance financing note |
— |
— |
— |
41,935 |
|||
Payment for short-term insurance financing note |
— |
(11,068) |
(15,330) |
(27,887) |
|||
Payment for finance lease liabilities |
(1,372) |
(1,173) |
(4,977) |
(3,088) |
|||
Proceeds from borrowings |
9,590 |
— |
29,818 |
— |
|||
Repayments for borrowings |
(13,570) |
— |
(20,223) |
— |
|||
Proceeds from failed sale-leaseback transaction |
— |
— |
31,700 |
— |
|||
Repurchase of Series B convertible preferred stock |
— |
— |
— |
(3,000) |
|||
Proceeds from issuance of Series D convertible preferred stock |
— |
— |
— |
3,000 |
|||
Proceeds from issuance of Series E convertible preferred stock |
— |
— |
— |
600,000 |
|||
Proceeds from exercise of stock options |
3,050 |
2,105 |
17,788 |
8,132 |
|||
Proceeds from the exercise of public warrants |
— |
— |
— |
173,273 |
|||
Proceeds from the reverse capitalization |
— |
— |
— |
4,439,153 |
|||
Payment of transaction costs related to the reverse recapitalization |
— |
(34,054) |
— |
(38,865) |
|||
Proceeds from employee stock purchase plan |
11,680 |
— |
24,562 |
— |
|||
|
— |
(20,716) |
— |
(20,716) |
|||
Stock repurchases from employees for tax withholdings |
(5,894) |
(22,063) |
(218,789) |
(22,063) |
|||
Payment for credit facility issuance costs |
— |
— |
(6,631) |
— |
|||
Net cash provided by financing activities |
1,512,801 |
1,899,585 |
1,347,235 |
7,136,428 |
|||
Net increase (decrease) in cash, cash equivalents, and restricted cash |
471,630 |
1,465,454 |
(4,560,700) |
5,657,602 |
|||
Beginning cash, cash equivalents, and restricted cash |
1,265,690 |
4,832,566 |
6,298,020 |
640,418 |
|||
Ending cash, cash equivalents, and restricted cash |
$ 1,737,320 |
$ 6,298,020 |
$ 1,737,320 |
$ 6,298,020 |
|
|||||||
Adjusted EBITDA |
|||||||
Three Months Ended |
Twelve Months Ended |
||||||
2022 |
2021 |
2022 |
2021 |
||||
Net loss (GAAP) |
$ (472,648) |
$ (1,045,680) |
$ (1,304,460) |
$ (2,579,761) |
|||
Interest expense |
8,075 |
1,263 |
30,596 |
1,374 |
|||
Interest income |
(29,472) |
— |
(56,756) |
— |
|||
Provision for (benefit from) income taxes |
(161) |
18 |
379 |
49 |
|||
Depreciation and amortization |
55,240 |
36,286 |
186,583 |
62,907 |
|||
Change in fair value of forward contracts |
— |
— |
— |
454,546 |
|||
Change in fair value of convertible preferred stock warrant liability |
— |
— |
— |
6,976 |
|||
Change in fair value of common stock warrant liability |
(255,899) |
557,973 |
(1,254,218) |
582,760 |
|||
Transaction costs expensed |
— |
— |
— |
2,717 |
|||
Stock-based compensation |
71,255 |
150,557 |
423,500 |
516,757 |
|||
Adjusted EBITDA (non-GAAP) |
$ (623,610) |
$ (299,583) |
$ (1,974,376) |
$ (951,675) |
Free Cash Flow |
||||||||
Three Months Ended |
Twelve Months Ended |
|||||||
2022 |
2021 |
2022 |
2021 |
|||||
Net cash used in operating activities (GAAP) |
$ (648,515) |
$ (312,732) |
$ (2,226,258) |
$ (1,058,133) |
||||
Capital expenditures |
(289,888) |
(121,907) |
(1,074,852) |
(421,220) |
||||
Free cash flow (non-GAAP) |
$ (938,403) |
$ (434,639) |
$ (3,301,110) |
$ (1,479,353) |
___________________________________ |
1 The business combination (the "Merger") between |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-announces-fourth-quarter-and-full-year-2022-financial-results-exceeds-annual-production-guidance-with-3-493-vehicles-in-q4-and-7-180-in-the-full-year-2022--301753593.html
SOURCE